Many physicians have been reluctant to prescribe Merck’s COVID-19 antiviral, molnupiravir, because it’s less effective at preventing severe outcomes, NPR reported Feb. 22.
Read the full post on Becker's Hospital Review - Healthcare News
Physicians find limited use for Merck’s COVID-19 antiviral
